Global Thyroid Gland Disorder Treatment Market Growth (Status and Outlook) 2023-2029

Global Thyroid Gland Disorder Treatment Market Growth (Status and Outlook) 2023-2029

Hormones released by thyroid gland play a crucial role in stimulating metabolism, growth, and calories processing. Globally, thyroid gland disorders such as hypothyroidism, hyperthyroidism, and thyroid nodules affect around 5% to 10% of the population. Hyperthyroidism and hypothyroidism affect majority of the population primarily due to growing incidence of autoimmune diseases such as Grave’s disease and Hashimoto's thyroiditis. Moreover, iodine deficiency is a widespread problem across the globe and is measured as a prime risk factor for the increase in prevalence of thyroid disorders.

LPI (LP Information)' newest research report, the “Thyroid Gland Disorder Treatment Industry Forecast” looks at past sales and reviews total world Thyroid Gland Disorder Treatment sales in 2022, providing a comprehensive analysis by region and market sector of projected Thyroid Gland Disorder Treatment sales for 2023 through 2029. With Thyroid Gland Disorder Treatment sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Thyroid Gland Disorder Treatment industry.

This Insight Report provides a comprehensive analysis of the global Thyroid Gland Disorder Treatment landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Thyroid Gland Disorder Treatment portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Thyroid Gland Disorder Treatment market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Thyroid Gland Disorder Treatment and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Thyroid Gland Disorder Treatment.

The global Thyroid Gland Disorder Treatment market size is projected to grow from US$ 2123 million in 2022 to US$ 2563.2 million in 2029; it is expected to grow at a CAGR of 2.7% from 2023 to 2029.

The major factors that drive the growth of the market include increase in the incidence of thyroid gland disorder, rise in the number of disease awareness programs especially in the developing countries, and development of effective combination drug therapies to treat thyroid gland disorder. However, side effects of the drugs and stringent government regulations hamper the market growth. Moreover, availability of large pool of undiagnosed patients due to asymptomatic nature of thyroid disorders help open new avenues for the market growth during the forecast period.

This report presents a comprehensive overview, market shares, and growth opportunities of Thyroid Gland Disorder Treatment market by product type, application, key players and key regions and countries.

Market Segmentation:

Segmentation by type
Hyperthyroidism
Hypothyroidism
Others

Segmentation by application
Men
Women

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Abbott
bioMérieux
Danaher
DiaSorin
Siemens Healthineers

Please note: The report will take approximately 2 business days to prepare and deliver.